dc.creator | Miró-Canturri, Andrea | es |
dc.creator | Ayerbe Algaba, Rafael | es |
dc.creator | Toro Estévez, Raquel del | es |
dc.creator | Jiménez-Mejías, Manuel Enrique | es |
dc.creator | Pachón Díaz, Jerónimo | es |
dc.creator | Smani, Younes | es |
dc.date.accessioned | 2021-07-05T10:16:08Z | |
dc.date.available | 2021-07-05T10:16:08Z | |
dc.date.issued | 2021-05-26 | |
dc.identifier.citation | Miró-Canturri, A., Ayerbe Algaba, R., Toro Estévez, R.d., Jiménez-Mejías, M.E., Pachón Díaz, J. y Smani, Y. (2021). Potential tamoxifen repurposing to combat infections by multidrug-resistant Gram-negative bacilli. Pharmaceuticals, 14 (6) | |
dc.identifier.issn | 1424-8247(electrónico) | es |
dc.identifier.uri | https://hdl.handle.net/11441/115124 | |
dc.description.abstract | The development of new strategic therapies for multidrug-resistant bacteria, like the
use of non-antimicrobial approaches and/or drugs repurposed to be used as monotherapies or in
combination with clinically relevant antibiotics, has become urgent. A therapeutic alternative for
infections by multidrug-resistant Gram-negative bacilli (MDR-GNB) is immune system modulation to
improve the infection clearance. We showed that immunocompetent mice pretreated with tamoxifen
at 80 mg/kg/d for three days and infected with Acinetobacter baumannii, Pseudomonas aeruginosa,
or Escherichia coli in peritoneal sepsis models showed reduced release of the monocyte chemotactic
protein-1 (MCP-1) and its signaling pathway interleukin-18 (IL-18), and phosphorylated extracellular
signal-regulated kinase 1/2 (ERK1/2). This reduction of MCP-1 induced the reduction of migration of
inflammatory monocytes and neutrophils from the bone marrow to the blood. Indeed, pretreatment
with tamoxifen in murine peritoneal sepsis models reduced the bacterial load in tissues and blood,
and increased mice survival from 0% to 60–100%. Together, these data show that tamoxifen presents
therapeutic efficacy against MDR A. baumannii, P. aeruginosa, and E. coli in experimental models of
infection and may be a new candidate to be repurposed as a treatment for GNB infections. | es |
dc.description.sponsorship | Instituto de Salud Carlos III , CP15/00132; PI16/01378; PI19/01453; RD16/0016/0009 | es |
dc.format | application/pdf | es |
dc.format.extent | 17 p. | es |
dc.language.iso | eng | es |
dc.relation.ispartof | Pharmaceuticals, 14 (6) | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Repurposing drug | es |
dc.subject | Tamoxifen | es |
dc.subject | Bacteria | es |
dc.subject | Infection | es |
dc.subject | Animal model | es |
dc.subject | Immune system | es |
dc.title | Potential tamoxifen repurposing to combat infections by multidrug-resistant Gram-negative bacilli | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Fisiología Médica y Biofísica | es |
dc.contributor.affiliation | Instituto de Biomedicina de Sevilla (IBIS) | es |
dc.relation.projectID | CP15/00132 | es |
dc.relation.projectID | PI16/01378 | es |
dc.relation.projectID | PI19/01453 | es |
dc.relation.projectID | RD16/0016/0009 | es |
dc.relation.publisherversion | https://www.mdpi.com/1424-8247/14/6/507 | es |
dc.identifier.doi | 10.3390/ph14060507 | es |
dc.journaltitle | Pharmaceuticals | es |
dc.publication.volumen | 14 | es |
dc.publication.issue | 6 | es |